May 13, 2010 | Pathway Genomics announced earlier this week that the company would sell its Insight genomics test at 6,000 Walgreens stores. Pathway said the tests would be available on Friday. Critics called the move "reckless" with the potential to be "powerfully bad." (Washington Post). On Thursday, Walgreens announced that they would not be carrying the test after a May 10 FDA letter was made public giving Pathway Genomics 15 days to explain why the company did not obtain FDA clearance or approval for the test. Pathway officials have said that the test is in compliance with federal regulations, but a Walgreens spokesperson said that the drug store has chosen not to offer the test to customers until "we have further clarity on this matter." (LA Times)